A5074749952- Mesenchymal stem cell research
- Biomedical Ethics and Regulation
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Tissue Engineering and Regenerative Medicine
- Immunotherapy and Immune Responses
- Pluripotent Stem Cells Research
- Immune Cell Function and Interaction
- Periodontal Regeneration and Treatments
- Osteoarthritis Treatment and Mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Virus-based gene therapy research
- T-cell and B-cell Immunology
- Radiopharmaceutical Chemistry and Applications
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Autoimmune and Inflammatory Disorders Research
- Acute Myeloid Leukemia Research
- Diabetic Foot Ulcer Assessment and Management
- Angiogenesis and VEGF in Cancer
- Skin and Cellular Biology Research
- Chronic Lymphocytic Leukemia Research
- RNA Interference and Gene Delivery
- Peripheral Artery Disease Management
RELX Group (United States)
2020
University Medical Center Utrecht
2009-2019
Utrecht University
2003-2015
European Society for Blood and Marrow Transplantation
2011
University Hospital Leipzig
2011
Radboud University Nijmegen
2011
Leiden University
2011
Hospital Clínic de Barcelona
2007
Sanquin
1999
University of Amsterdam
1994-1999
Extracellular vesicles (EVs), such as exosomes and microvesicles, are released by different cell types participate in physiological pathophysiological processes. EVs mediate intercellular communication cell‐derived extracellular signalling organelles that transmit specific information from their of origin to target cells. As a result these properties, defined may serve novel tools for various therapeutic approaches, including (a) anti‐tumour therapy, (b) pathogen vaccination, (c)...
Traditionally, mesenchymal stem cells (MSCs) isolated from adult bone marrow were described as being capable of differentiating to various lineages including cartilage. Despite increasing interest in these MSCs, concerns regarding their safety, vivo behavior and clinical effectiveness have restrained application. We hypothesized that MSCs trophic effects stimulate recycled chondrons (chondrocytes with native pericellular matrix) regenerate Searching for a proof principle, this phase I...
Background— Patients with severe limb ischemia may not be eligible for conventional therapeutic interventions. Pioneering clinical trials suggest that bone marrow–derived cell therapy enhances neovascularization, improves tissue perfusion, and prevents amputation. The objective of this trial was to determine whether repetitive intra-arterial infusion marrow mononuclear cells (BMMNCs) in patients severe, nonrevascularizable can prevent major Methods Results— Rejuvenating Endothelial...
Abstract MSCs are known as multipotent mesenchymal stem cells that have been found capable of differentiating into various lineages including cartilage. However, recent studies suggest pericytes stimulate tissue repair through trophic signaling. Aimed at articular cartilage in a one-stage cell transplantation, this study provides first clinical evidence autologous the knee without engrafting host tissue. A phase I (first-in-man) trial studied application allogeneic mixed with 10% or 20%...
A comprehensive quality management system called JACIE (Joint Accreditation Committee International Society for Cellular Therapy and the European Group Blood Marrow Transplantation), was introduced to improve of care in hematopoietic stem-cell transplantation (HSCT). We therefore tested hypothesis that introduction improved patient survival.Data on 41,623 allogeneic (39%) 66,281 autologous (61%) HSCTs an acquired hematologic disorder performed between 1999 2007 by 421 teams Europe were used...
Intranasal treatment with C57BL/6 MSCs reduces lesion volume and improves motor cognitive behavior in the neonatal hypoxic-ischemic (HI) mouse model. In this study, we investigated potential of human (hMSCs) to treat HI brain injury mouse. Assessing regenerative capacity hMSCs is crucial for translation our knowledge clinic. We determined neuroregenerative vitro vivo by intranasal administration 10 d post-HI mice. was induced P9 pups. 1×106 or 2×106 were administered intranasally post-HI....
Using a combination of articular chondrocytes (ACs) and mesenchymal stromal cells (MSCs) has shown to be viable option for single-stage cell-based treatment focal cartilage defects. However, there is still considerable debate whether MSCs differentiate or have chondroinductive role through trophic factors. In addition, it remains unclear direct cell-cell contact necessary chondrogenesis. Therefore, the aim this study was investigate indirect between ACs essential increased production in...
BackgroundRecessive dystrophic epidermolysis bullosa (RDEB) is a hereditary blistering disorder due to lack of type VII collagen. At present, treatment mainly supportive.ObjectivesTo determine whether intravenous allogeneic bone marrow–derived mesenchymal stromal/stem cells (BM-MSCs) are safe in RDEB adults and if the improve wound healing quality life.MethodsWe conducted prospective, phase I/II, open-label study recruiting 10 receive 2 infusions BM-MSCs (on day 0 14; each dose 2-4 × 106...
In tissue engineering, strategies are being developed to repair large bone defects by combining biomaterials and marrow-derived multipotent mesenchymal stromal cells (MSCs). For expansion of MSCs under good manufacturing practice conditions, human platelet lysate (PL) can serve as substitute for fetal bovine serum (FBS) in culture media. We compared the vivo bone-forming capacity passage 3 cultured with either PL or FBS nine different donors. also tested growth kinetics, antigen expression...
Abstract Purpose: Engineering T cells with receptors to redirect the immune system against cancer has most recently been described as a scientific breakthrough. However, main challenge remains GMP-grade purification of selectively expressing introduced receptor in order reduce potential side effects due poorly or nonengineered cells. Experimental Design: In test novel strategy, we took advantage model γδT cell (TCR), naturally interfering endogenous TCR expression and designed optimal...
<h2>Abstract</h2><h3>Background aims</h3> As part of the advanced therapy medicinal product (ATMP) regulation, hospital exemption (HE) was enacted to accommodate manufacturing custom-made ATMPs for treatment purposes in European Union (EU). However, how HE pathway has been used practice is largely unknown. <h3>Methods</h3> Using a survey and interviews, we provide characteristics, scale motivation ATMP under other, non-ATMP-specific pathways seven countries. <h3>Results</h3> Results show...
Thanks to the coordinated efforts of four major scientific organizations, this report describes "novel cellular therapy" activity in Europe for year 2009. Fifty teams from 22 countries reported data on 814 patients using a dedicated survey, which were combined additional 328 records by 55 standard European Blood and Marrow Transplantation (EBMT) database. Indications cardiovascular (37%; 64% autologous), graft-vs.-host disease (27%; 7% musculoskeletal (17%; 98% epithelial/parenchymal (8%;...
Studies on radiolabeled monoclonal antibodies (MoAb) have dealt mainly with single antibodies. However, major differences may exist among different MoAb that bind to the same antigen and between switch variants of antibody. This study evaluates compares a series specificities, subclasses, isotypes applicable in treatment patients B cell malignancies.MoAb were iodinated iodogen. Immunoreactivity was determined binding assays. Scatchard analyses performed determine association constants...
JACIE was initiated as a small pilot project in Spain 2000 and launched formal Europe-wide inspection program January 2004. since 2000, over 150 applications for accreditation have been received by the office more than 130 inspections completed European centers facilities. Almost all of these were found to be functioning at high level excellence, with majority having only minor deficiencies compliance standards. In one-third there significant deficiencies. The most common quality management....